In a recent development, Bank of America analyst Alec Stranahan has revised the price target for Day One Biopharmaceuticals (DAWN, Financial), lowering it from $24 to $21 while maintaining a Buy rating on the shares. This adjustment comes as investors prepare for the upcoming Q1 earnings season, which will largely concentrate on the launch of commercial products within the small to mid-cap biotech sector.
Stranahan notes that discussions surrounding pharmaceutical tariffs, the impact of tax changes, and turnover within the FDA are expected to influence market sentiment during this period. These factors could provide an additional perspective as investors evaluate biotech firms' performance and strategy.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for Day One Biopharmaceuticals Inc (DAWN, Financial) is $30.29 with a high estimate of $36.00 and a low estimate of $21.00. The average target implies an upside of 348.01% from the current price of $6.76. More detailed estimate data can be found on the Day One Biopharmaceuticals Inc (DAWN) Forecast page.
Based on the consensus recommendation from 9 brokerage firms, Day One Biopharmaceuticals Inc's (DAWN, Financial) average brokerage recommendation is currently 1.9, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
